DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Clinical trial NCT02633111 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02633111
Sponsor: Memorial Sloan Kettering Cancer Center
Status: ACTIVE_NOT_RECRUITING
Study type: OBSERVATIONAL

B-cell Non-Hodgkin Lymphoma Aggressive

Start date: 2015-10-01
Primary completion: 2026-10-01
Enrollment: 501

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.